Details for Patent: 8,426,392

Which drugs does patent 8,426,392 protect, and when does it expire?

Patent 8,426,392 protects ELLA and is included in one NDA.

This patent has one patent family member in one country.

Summary for Patent: 8,426,392

Title:	Method for providing emergency contraception
Abstract:	The invention provides a method for providing emergency contraception in a female subject, comprising providing the subject with a therapeutically effective amount of ulipristal acetate in an oral dosage form before, during or after a meal. The invention further provides a kit comprising i) an oral dosage form comprising ulipristal acetate and ii) a printed matter stating that ulipristal acetate may be taken with or without food.
Inventor(s):	Gainer; Erin (Paris, FR), Mathe; Henri Camille (Paris, FR)
Assignee:	Laboratoire HRA-Pharma (Paris, FR)
Application Number:	12/633,885
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,426,392
Patent Claim Types: see list of patent claims	Use; Dosage form;

Drugs Protected by US Patent 8,426,392

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Lab Hra Pharma	ELLA	ulipristal acetate	TABLET;ORAL	022474-001	Aug 13, 2010	AB	RX	Yes	Yes						ELLA IS A PROGESTERONE AGONIST/ANTAGONIST EMERGENCY CONTRACEPTION INDICATED FOR THE PREVENTION OF PREGNANCY FOLLOWING UNPROTECTED INTERCOURSE OR A KNOWN OR SUSPECTED CONTRACEPTIVE FAILURE. ELLA CAN BE TAKEN WITH OR WITHOUT FOOD

International Family Members for US Patent 8,426,392

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
World Intellectual Property Organization (WIPO)	2011069871